Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants

This trial assessed whether expectant management or active treatment (medication) for patent ductus arteriosus reduces the risk of death or bronchopulmonary dysplasia in preterm infants born between 22 and 28 weeks’ gestation.

Publication Details

Journal
JAMA
Published
2025-12-09
DOI
https://doi.org/10.1001/jama.2025.23333
Citations
1
Primary Topic
Cardiovascular Conditions and Treatments
Type
article
Field-Weighted Citation Impact
1.36
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants

1 citations
JAMA
Cardiovascular Conditions and Treatments
1.36
article

Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants

article en
1 citations

Abstract

This trial assessed whether expectant management or active treatment (medication) for patent ductus arteriosus reduces the risk of death or bronchopulmonary dysplasia in preterm infants born between 22 and 28 weeks’ gestation.

JAMAVol. 335(7)
Openalex Percentile: Top 14%
Cardiovascular Conditions and Treatments
1.36
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants · JAMA (2025) | TGRS Research Map | TGRS